Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis

BJU International

Volumn 104, Issue 11, 2009, Pages 1637-1640

  Planas, Jacques ^a   Trilla, Enrique ^a   Raventós, Carles ^a   Cecchini, Lluis ^a   Orsola, Anna ^a   Salvador, Carles ^a   Placer, Jose ^a   Encabo, Gloria ^a   Morote, Juan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Androgen deprivation therapy; Bisphosphonates; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; CALCIUM; GONADORELIN AGONIST; VITAMIN D;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FEMUR NECK FRACTURE; FOLLOW UP; FRAGILITY FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SCORING SYSTEM;

EID: 70449371334     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08622.x     Document Type: Article

References (17)

1. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997 79 : 235 246
2. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 : 295 300
3. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 1788
4. Daniell H. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997 157 : 439 444
5. Shahinian V, Kuo Y, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 164
6. Morote J, Orsola A, Abascal J et al. Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression. J Urol 2006 175 : 1679 1683
7. Morote J, Martinez E, Trilla E et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003 44 : 661 665
8. Oefelein M, Ricchiuti V, Conrad W et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002 168 : 1005 1007
9. Higano C. Management of bone loss in men with prostate cancer. J Urol 2003 170 : 59 63
10. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study Osteoporotic Fractures Research Group. Lancet 1993 341 : 72 5
11. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000 343 : 604 610
12. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 345 : 948 955
13. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003 169 : 2008 2012
14. Israeli RS, Rosenberg SJ, Saltzstein DR et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007 5 : 271 277
15. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007 25 : 1038 1042
16. Bruder JM, Ma JZ, Wing N et al. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 2006 9 : 431 437
17. Greenspan SL, Nelson JB, Trump DL et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007 146 : 416 424